Loading...

3D Medicines Inc.

1244.HK•HKSE
Healthcare
Biotechnology
HK$4.05
HK$0.04(1.00%)

3D Medicines Inc. (1244.HK) Stock Overview

Explore 3D Medicines Inc.’s financial performance, market position, analyst ratings, and future outlook.

Meyka AI Score

B

Score: 61.1/100

Key Financials

Market Cap992.4M
P/E Ratio-4.95
EPS (TTM)$-0.82
ROE-0.22%
Fundamental Analysis

AI Price Forecasts

1 Week$4.67
1 Month$3.14
3 Months$0.00
1 Year Target$0.36

1244.HK Stock Analysis & Investment Overview

Our comprehensive AI-powered analysis of 3D Medicines Inc. (1244.HK) provides investors with deep insights into the stock's performance, growth potential, and market positioning. With a Meyka AI Score of B, this stock demonstrates moderate investment characteristics based on our advanced machine learning models.

The current technical analysis reveals key indicators including an RSI of 73.26, suggesting the stock is in an overbought condition. Our forecasting models predict significant price movements, with a 12-month target of $0.36.

Key financial metrics showcase the company's fundamental strength, including a P/E ratio of -4.95 and a market capitalization of 992.4M. These metrics, combined with our AI analysis, provide a comprehensive view for both institutional and retail investors.

Technical Indicators

73.26RSI (14)
0.24MACD
23.30ADX
Stats data is not available for 1244.HKStats details for 1244.HK are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.
Analyst Recommendations data is not available for 1244.HKAnalyst Recommendations details for 1244.HK are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.

Company Profile

3D Medicines Inc., a biopharmaceutical company, researches, develops, and commercializes oncology products and drug candidates for the treatment of patients with various cancers in Mainland China. It offers Envafolimab, a PD-L1 antibody in the form of subcutaneous injection for the treatment of previously treated microsatellite instability-high (MSI-H)/mismatch repair deficient(dMMR) advanced solid tumors. The company's products in development pipeline include 3D189 for multi-indication tumor and is in phase III clinical trial; 3D229 (GAS6/AXL) for non-small cell lung cancer, ovarian cancer, and kidney cancer and is in phase III clinical trial; 3D1001 for the treatment of postoperative dental pain and tumor pain which is in phase II trial; 3D1002 for oncology pain and is in phase II trial; and 3D185, which is in phase I clinical trial for the treatment of locally advanced or metastatic solid tumors, as well as other products, such as 3D197 for multi-indication tumor immunotherapy, 3D011 for advanced malignant solid tumor, and 3D057 for multiple indications tumors. 3D Medcines Inc. was founded in 2014 and is headquartered in Qingdao, China.

CEO

Zhaolong Gong

Employees

191

Headquarters

No. 3 and No. 5, Laiyang Road, Qingdao

Founded

2022

Frequently Asked Questions

;